Cite
p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682)
MLA
D’Amico, Anthony V., et al. “P53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682).” Urology, vol. 71, no. 5, May 2008, pp. 933–37. EBSCOhost, https://doi.org/10.1016/j.urology.2007.11.005.
APA
D’Amico, A. V., Halabi, S., Vollmer, R., Loffredo, M., McMahon, E., Sanford, B., Archer, L., Vogelzang, N. J., Small, E. J., & Kantoff, P. W. (2008). p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology, 71(5), 933–937. https://doi.org/10.1016/j.urology.2007.11.005
Chicago
D’Amico, Anthony V., Susan Halabi, Robin Vollmer, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Laura Archer, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. 2008. “P53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682).” Urology 71 (5): 933–37. doi:10.1016/j.urology.2007.11.005.